Failure-prone Unum cuts jobs, loses scientific chief, and changes focus yet again
Atlas Venture-backed Unum, which once harbored ambitions to rival the two CAR-T therapies Kymriah and Yescarta, is paying the price for a laundry list of setbacks.
On Monday, the Cambridge, Massachusetts-based company said it was cutting its workforce by 43 employees (roughly 60% of the total headcount) to focus its efforts on a preclinical program. It also disclosed the departure of its chief scientific officer, Seth Ettenberg, as it ceases the development of trials harnessing its maiden technology: ACTR.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.